Annovis Bio Inc
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinic… Read more
Annovis Bio Inc (ANVS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.265x
Based on the latest financial reports, Annovis Bio Inc (ANVS) has a cash flow conversion efficiency ratio of -0.265x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.49 Million) by net assets ($13.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Annovis Bio Inc - Cash Flow Conversion Efficiency Trend (2009–2024)
This chart illustrates how Annovis Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Annovis Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Annovis Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Equatorial Pará Distribuidora de Energia S.A
SA:EQPA3
|
0.156x |
|
Shanghai Huili Building Materials Co Ltd
SHG:900939
|
-0.016x |
|
UNITED FOODBRANDS LIMITED
NSE:UFBL
|
0.243x |
|
Harford Bank
PINK:HFBK
|
0.022x |
|
Teleste Oyj
HE:TLT1V
|
0.087x |
|
6934
TWO:6934
|
-0.102x |
|
Ta-Yuan Cogeneration Co Ltd
TWO:8931
|
0.116x |
|
ASICLAND
KQ:445090
|
-0.133x |
Annual Cash Flow Conversion Efficiency for Annovis Bio Inc (2009–2024)
The table below shows the annual cash flow conversion efficiency of Annovis Bio Inc from 2009 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $9.31 Million | $-21.89 Billion | -2352.325x | -45718.55% |
| 2023-12-31 | $-7.75 Million | $-39.97 Million | 5.157x | +943.59% |
| 2022-12-31 | $28.32 Million | $-17.31 Million | -0.611x | -197.82% |
| 2021-12-31 | $44.49 Million | $-9.13 Million | -0.205x | +61.02% |
| 2020-12-31 | $7.54 Million | $-3.97 Million | -0.527x | -1047.67% |
| 2019-12-31 | $-8.58 Million | $-476.54K | 0.056x | -24.46% |
| 2018-12-31 | $-7.59 Million | $-558.61K | 0.074x | -4.67% |
| 2017-12-31 | $-6.97 Million | $-537.48K | 0.077x | +114.53% |
| 2012-12-31 | $2.66 Million | $-1.41 Million | -0.531x | -145.69% |
| 2011-12-31 | $13.93 Million | $-3.01 Million | -0.216x | -100.99% |
| 2010-12-31 | $16.49 Million | $-1.77 Million | -0.108x | +59.22% |
| 2009-12-31 | $1.48 Million | $-389.23K | -0.264x | -- |